L. Pieri

发表

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.

M. Cazzola, G. Martinelli, P. Guglielmelli, 2011, Blood.

BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.

P. Guglielmelli, A. Vannucchi, L. Pieri, 2012, Future oncology.

M. Cazzola, M. Baccarani, T. Barbui, 2012, American journal of hematology.

Low bone mass and hypovitaminosis D in haemophilia: A single‐centre study in patients with severe and moderate haemophilia A and B

L. Tofani, G. Castaman, S. Linari, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

T. Barbui, G. Leone, P. Guglielmelli, 2008, Haematologica.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

M. Cazzola, T. Barbui, H. Kantarjian, 2017, Blood.

Givinostat for the treatment of polycythemia vera

P. Guglielmelli, A. Vannucchi, L. Pieri, 2014 .

based on the burden of JAK2V617F mutated allele Identification of patients with poorer survival in primary myelofibrosis

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2013 .

JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment

P. Guglielmelli, A. Vannucchi, L. Pieri, 2011, Therapeutic advances in hematology.

Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome–Negative Myeloproliferative Neoplasms

D. Palli, F. Annunziato, P. Guglielmelli, 2009, Cancer Epidemiology Biomarkers & Prevention.

Treatment options for essential thrombocythemia and polycythemia vera

P. Guglielmelli, A. Bosi, A. Vannucchi, 2009, Expert review of hematology.

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

P. Guglielmelli, C. Bogani, A. Bosi, 2009, Haematologica.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2008, Haematologica.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia

T. Barbui, G. Leone, P. Guglielmelli, 2007 .

Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative ‘idiopathic’ erythrocytosis

P. Guglielmelli, A. Pancrazzi, A. Bosi, 2013, Haematologica.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

C. Bogani, M. Le Bousse-Kerdilès, A. Vannucchi, 2015, Haematologica.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

T. Barbui, D. Larson, P. Guglielmelli, 2014, Blood.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

M. Cazzola, C. Pascutto, D. Colomer, 2014, Blood.

Management of thrombocytopenia in cancer.

G. Castaman, L. Pieri, 2018, Thrombosis research.

Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study

T. Barbui, A. Vannucchi, I. Martinelli, 2014, American journal of hematology.

Influence of the Jak2 V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.

P. Guglielmelli, C. Bogani, A. Pancrazzi, 2006 .

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

M. Cazzola, P. Guglielmelli, R. Manfredini, 2014, Blood.

treated with ruxolitinib in the COMFORT-II study Impact of mutational status on outcomes in myelofibrosis patients

M. Cazzola, R. Manfredini, A. Vannucchi, 2014 .

myelofibrosis in primary MPL , or CALR , JAK2 Clinical effect of driver mutations of

M. Cazzola, C. Pascutto, D. Colomer, 2014 .

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

M. Cazzola, T. Barbui, D. Larson, 2013, Leukemia.

phase 1/2 study in patients with myelofibrosis Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a

P. Guglielmelli, A. Pancrazzi, A. Bosi, 2012 .

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2011, Blood.

Ruxolitinib‐induced reversal of alopecia universalis in a patient with essential thrombocythemia

P. Guglielmelli, A. Vannucchi, L. Pieri, 2015, American journal of hematology.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

S. Verstovsek, P. Guglielmelli, A. Pancrazzi, 2015, Blood.

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

P. Guglielmelli, A. Pancrazzi, A. Bosi, 2014, Blood.

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2010, Haematologica.

The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia

A. Vannucchi, A. Jones, N. Cross, 2011, Annals of Hematology.

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

P. Guglielmelli, A. Pancrazzi, A. Bosi, 2010, Leukemia.

Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study

M. Cazzola, T. Barbui, A. Vannucchi, 2011 .

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis

P. Guglielmelli, A. Bosi, G. Barosi, 2009, Haematologica.

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera

P. Guglielmelli, C. Bogani, A. Bosi, 2009 .

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

M. Cazzola, T. Barbui, P. Guglielmelli, 2017, Leukemia.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

M. Cazzola, T. Barbui, P. Guglielmelli, 2016, American journal of hematology.

Validation of the Mayo alliance prognostic system for mastocytosis

P. Guglielmelli, F. Mannelli, A. Vannucchi, 2019, Blood Cancer Journal.

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

M. Le Bousse-Kerdilès, A. Vannucchi, M. Bourgeade, 2015, Cancer research.

Rationale for combination therapies in myelofibrosis

P. Guglielmelli, A. Vannucchi, N. Bartalucci, 2015 .

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera

M. Cazzola, T. Barbui, A. Vannucchi, 2014, British journal of haematology.

essential thrombocythemia, polycythemia vera, and myelofibrosis Long-term survival and blast transformation in molecularly annotated

T. Barbui, D. Larson, P. Guglielmelli, 2014 .

The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry.

M. Triggiani, M. Rondoni, E. Difonzo, 2018, Future oncology.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

M. Griesshammer, T. Barbui, G. Gaidano, 2016, Blood Cancer Journal.

Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms

M. Cazzola, T. Barbui, G. Cimino, 2017, American journal of hematology.

The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics.

A. Vannucchi, L. Pieri, I. Loiacono, 2013, Leukemia research.

Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia

T. Barbui, G. Leone, P. Guglielmelli, 2009, American journal of hematology.

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

T. Barbui, G. Leone, P. Guglielmelli, 2010, Annals of Hematology.

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

M. Triggiani, M. Rondoni, G. Martinelli, 2016, American journal of hematology.

The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera

M. Cazzola, T. Barbui, A. Vannucchi, 2017, American journal of hematology.

Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele.

P. Guglielmelli, C. Bogani, A. Bosi, 2008, Leukemia research.

Chronic Myeloproliferative Neoplasms: a Collaborative Approach

P. Guglielmelli, A. Vannucchi, L. Pieri, 2010, Mediterranean journal of hematology and infectious diseases.

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

A. Bosi, A. Vannucchi, L. Pieri, 2011, Blood.

Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution

L. Pieri, C. Carulli, R. Civinini, 2021, International Journal of Bone Fragility.

Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown

J. Voorberg, G. Castaman, K. Fijnvandraat, 2018, Seminars in Thrombosis and Hemostasis.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

M. Cazzola, T. Barbui, H. Kantarjian, 2013, Cancer.

Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2

M. Cazzola, C. Bock, M. Steurer, 2013, PloS one.

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

M. Cazzola, M. Steurer, P. Guglielmelli, 2012, American journal of hematology.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

T. Barbui, A. Vannucchi, F. Passamonti, 2014, Blood.

Mutations and prognosis in primary myelofibrosis

M. Cazzola, R. Zini, R. Laborde, 2013, Leukemia.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

D. Gilliland, O. Abdel-Wahab, O. Kilpivaara, 2010, Leukemia.

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

T. Barbui, A. Vannucchi, F. Passamonti, 2012, Blood.

Masked polycythemia Vera (mPV): Results of an international study

T. Barbui, A. Vannucchi, A. Tefferi, 2014, American journal of hematology.

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

P. Guglielmelli, A. Bosi, R. Manfredini, 2014, Leukemia.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

M. Cazzola, T. Barbui, P. Guglielmelli, 2019, American journal of hematology.

Kaposi sarcoma in a patient treated with ruxolitinib.

D. Massi, F. Annunziato, A. Vannucchi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

M. Cazzola, C. Pascutto, T. Barbui, 2014, Blood.

Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings

T. Barbui, G. Leone, A. Vannucchi, 2006 .

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

T. Barbui, F. Lo Coco, P. Guglielmelli, 2009, Blood.

Risk of second cancers in chronic myeloproliferative neoplasms.

D. Palli, P. Guglielmelli, A. Bosi, 2012, Blood.

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis

T. Barbui, A. Vannucchi, F. Passamonti, 2015, American journal of hematology.

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

T. Barbui, P. Guglielmelli, C. Bogani, 2009 .

Masked polycythemia Vera (mPV): Results of an international study

T. Barbui, A. Vannucchi, A. Tefferi, 2018, American journal of hematology.

Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene

A. Vannucchi, A. Tefferi, L. Pieri, 2014, American journal of hematology.

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

S. Ferrari, S. Ferrari, P. Guglielmelli, 2013, Leukemia.

MR Imaging in non‐hepatosplenic extramedullary hematopoiesis in primary myelofibrosis

R. Santi, A. Vannucchi, L. Pieri, 2016, American journal of hematology.

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis

F. Annunziato, P. Guglielmelli, F. Mannelli, 2019, American journal of hematology.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients

M. Cazzola, T. Barbui, P. Guglielmelli, 2015, American journal of hematology.

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

M. Cazzola, T. Barbui, H. Kantarjian, 2010 .

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

M. Cazzola, T. Barbui, H. Kantarjian, 2012 .

LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis

P. Guglielmelli, A. Vannucchi, A. Tefferi, 2010 .

Long-term Results From a Phase II Open-label Study of Ruxolitinib in Patients With Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

M. Cazzola, T. Barbui, Haifeng Zhang, 2014 .

Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm

M. Cazzola, T. Barbui, G. Cimino, 2015 .

A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results

M. Cazzola, T. Barbui, P. Guglielmelli, 2013 .

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

P. Guglielmelli, C. Bogani, A. Bosi, 2009 .

Disease correlates and clinical relevance of Hereditary Alpha-Tryptasemia in patients with Systemic Mastocytosis.

M. Triggiani, M. Brandi, R. Santi, 2022, The Journal of allergy and clinical immunology.

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience

G. Castaman, S. Linari, L. Pieri, 2023, Journal of clinical medicine.